No GP referral needed
| Consultant-led allergy, immunology & children's clinic · Marylebone, London
Mon–Sat, 9am–7pm
0207 637 9711
CONSULTANT IMMUNOLOGIST AND ALLERGIST
Dr. Gururaj
Arumugakani
MBBS · MRCP · MSc · PhD · FRCPath
Allergy Lead, UCLH
GMC: 6055399
BSACI registered
ROLE
Clinical Lead for Allergy, UCLH
PATIENTS
Adults & Adolescents 12+
SPECIAL INTERESTS
Allergy, Urticaria & Immunodeficiency
INSURANCE
Vitality & WPA Recognised
ABOUT
Dr Arumugakani
An expert in the field of Allergy and Immunology, Dr. Gururaj Arumugakani is a Consultant Allergist at UCLH. He specialises in all aspects of adult and adolescent allergy practice, including food, drug and inhalant allergy, venom allergy, urticaria and immunotherapy.
He began specialist training in 2006 and completed a PhD at the University of Leeds studying the role of B-cells in allergy and other immune-mediated conditions. He was appointed Consultant in Allergy and Immunology at Leeds Teaching Hospitals NHS Trust in 2016, before moving to London in 2024.
WHAT HE TREATS
Areas of Expertise
Food Allergy
Pet Allergy
Immunotherapy
Hay Fever & Inhalant Allergy
Venom Allergy
Immunodeficiency, incl. CVID
Drug and anaesthetic allergy
Urticaria & angioedema
Hereditary angioedema
“
A thorough, evidence-based approach - helping patients choose the investigations that are genuinely useful, and steering them away from the tests that aren't.
CLINICAL APPROACH
EXPERIENCE
Professional Background
Clinical governance lead for the Allergy and Clinical Immunology department in Leeds, and chair of the Immunoglobulin Panel.
Actively involved in the early trials of omalizumab (Xolair) for chronic urticaria, and helped pioneer home therapy for the condition.
Provides expert advice on allergy and immunology blood testing.
Member of the British Society of Allergy and Clinical Immunology (BSACI), the leading UK professional body in the field.
SELECTED WORK
Research & Publications
An active research portfolio spanning allergy, clinical immunology and immunodeficiency. Links go to the original peer-reviewed sources..
CHRONIC URTICARIA - PERSONALISED DOSING
Cost-effectiveness of personalised omalizumab dosing for chronic spontaneous urticaria
Denman S, Smith H, Arumugakani G, Mistry A, Savic S. Clinical and Experimental Dermatology, 2022; 47(11):2002–2005.
A ten-year cohort of 357 patients showing personalised dosing helped 22% of partial responders reach full symptom control, while reducing drug costs versus fixed-dose regimens.
B-CELL BIOLOGY
Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell Transition
Arumugakani G, Stephenson SJ, Newton DJ, et al. The Journal of Immunology, 2017; 198(10):3964–3972.
View on PubMed | DOI: 10.4049/jimmunol.1501761
Fundamental B-cell research underpinning Dr Arumugakani's PhD and his broader work in immune-mediated conditions.
IMMUNODEFICIENCY & COVID-19
Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK
Shields AM, Anantharachagan A, Arumugakani G, et al. Clinical and Experimental Immunology, 2022; 209(3):247–258.
View on PubMed | DOI: 10.1093/cei/uxac056
A national study of COVID-19 outcomes across primary and secondary immunodeficiency.
PRIMARY IMMUNODEFICIENCY - ICOS DEFICIENCY
Expanding Clinical Phenotype and Novel Insights into the Pathogenesis of ICOS Deficiency
Abolhassani H, El-Sherbiny YM, Arumugakani G, Carter C, et al. Journal of Clinical Immunology, 2020; 40(2):277–288.
View on PubMed | DOI: 10.1007/s10875-019-00738-0
Characterising the clinical picture and mechanisms of a rare inherited immunodeficiency.
CLINICAL REFERENCE - ANAESTHETIC ALLERGY
Anaesthetic Allergy — chapter contributor
In: Oxford Handbook of Anaesthesia, Oxford University Press.
An invited contribution to one of the most widely used clinical reference texts in UK anaesthetic practice.